The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of dose modification or termination of S-1 as adjuvant therapy on survival of locally advanced gastric cancer underwent curative gastrectomy.
 
Takeshi Kawakami
No Relationships to Disclose
 
Nozomu Machida
Honoraria - Taiho Pharmaceutical
 
Etsuro Bando
No Relationships to Disclose
 
Kaori Hayashi
No Relationships to Disclose
 
Hiromichi Shirasu
No Relationships to Disclose
 
Masahiro Kawahira
No Relationships to Disclose
 
Sadayuki Kawai
No Relationships to Disclose
 
Yosuke Kito
No Relationships to Disclose
 
Yukio Yoshida
No Relationships to Disclose
 
Satoshi Hamauchi
No Relationships to Disclose
 
Akiko Todaka
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Tomoya Yokota
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)
 
Akira Fukutomi
Honoraria - Taiho Pharmaceutical
 
Masanori Terashima
Honoraria - Chugai Pharma; Eisai; Lilly; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Otsuka (Inst); Yakult Honsha (Inst)
 
Hirofumi Yasui
No Relationships to Disclose